The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the Pharmaceuticals, Biotechnology and Generics sectors of the overall health care industry, backed by a team of respected writers with many years of experience in the field.
Actavis confirms plan to acquire Warner Chilcott, in $8.5 billion deal
20 May 2013
US generics major Actavis (NYSE: ACT) revealed today (May 20) that it has entered into a definitive
Latest Pharma Letter Articles
Positive Ph III results for Novo Nordisk's FIX derivative for hemophilia B
20 May 2013
Danish insulin giant Novo Nordisk (NOV: N) says it has completed paradigm 2, the first Phase
CIS countries prepare for the introduction of drug reimbursement schemes
20 May 2013
Russia, Ukraine and Kazakhstan have recently taken steps to introduce drug reimbursement schemes
Stallergenes and DBV Technologies partner on developing novel respiratory allergies treatments
20 May 2013
French biotech firms DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in
HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
20 May 2013
While the risks involved in HIV vaccine development have turned Big Pharma away from pursuing
Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
20 May 2013
One of the most important preconditions for Turkey to reach a reformist, sustainable economic
Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
20 May 2013
India's National Pharmaceutical Pricing Authority (NPPA) last week announced plans that will
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
